The use of surface marker identification and classification of cells is spreading beyond lymphocytes to the identification of monocytes, macrophages, myeloid stem cells, and tumor cells. A synergistic combination of the hybridoma technology with flow cytometry is further expanding the applications of both technologies. During the next five years, the main trend in cell surface marker analysis will be further simplification of the sample preparation and the analysis itself.
This report presents a detailed overview of the CD4, CD8 and CD34 Cell Surface Marker testing in the US, including clinical significance and current laboratory practice, as well as five-year test volume forecasts by market segment.